AbbVie to acquire cancer drug maker Pharmacyclics in $21bn deal

AbbVie

AbbVie has agreed to pay $261.25 for each share of Pharmacyclics.

US-based biopharmaceutical firm AbbVie announced Wednesday that it has agreed to acquire Pharmacyclics Inc for about $21 billion. The deal would give AbbVie control over Pharmacyclics’ flagship cancer drug Imbruvica, designed to treat hematologic malignancies.

Under the terms of the deal, which was approved by the boards of directors of both companies, AbbVie said it had agreed to pay $261.25 for each share of Pharmacyclics comprised of a mix of cash and AbbVie equity.

Pharmacyclics was nearing an agreement to be acquired by N.J.-based Johnson & Johnson, a longtime partner in developing Imbruvica, which was discussing a price of about $250 per share. However, AbbVie topped the offer at the last minute in order to take control over the Imbruvica drug.

In 2013, the U.S. Food and Drug Administration approved the drug and it is used to treat three different types of blood cancer. Besides that, the company said it could use its expertise in immunology to further improve the drug, which has already been approved in more than 40 countries.

Imbruvica generated net sales of $548 million in 2014 with $492 million of that in the United States. The sales estimated to hit more than $1 billion during this year. Imbruvica, which is taken orally is the only therapy to have received three breakthrough therapy designations by the FDA, is projected to hit $5 billion to $6 billion in sales at its peak.

With the acquisition of Imbruvica, AbbVie can initiate a powerful lead over competitors in the hematological oncology market, which the company estimated to be near $24 billion world-wide.

The new drug will also help the company branch out beyond its reliance on top-selling rheumatoid-arthritis therapy Humira and better cope with growing competition when the key U.S. patent for the drug expires in late 2016. Humira is AbbVie’s biggest-selling product, gaining $12.5 billion in sales in 2014. The patent lapse could prompt the introduction of biosimilar copies of Humira, however Imbruvica is protected against biosimilar rival products until 2026.

On Wednesday, AbbVie gained 1.09% and ended at $60.27 in New York, marking a one-year increase of 16.82%. During after-hours trading on Thursday, the stock slipped 0.12%. The company is valued at $95.03 billion.

 

 

Carrie Ann
Carrie Ann is Editor-in-Chief at Industry Leaders Magazine, based in Las Vegas. Carrie covers technology, trends, marketing, brands, productivity, and leadership. When she isn’t writing she prefers reading. She loves reading books and articles on business, economics, corporate law, luxury products, artificial intelligence, and latest technology. She’s keen on political discussions and shares an undying passion for gadgets. Follow Carrie Ann on Twitter, Facebook

Recent Posts

BlackRock ETFs breach $3 trillion mark in May

BlackRock ETFs breach $3 trillion mark in May

BlackRocks’ exchange-traded fund crossed $3 trillion for the first time in May, in sync with the ETF industry’s race to an all-time high of $9 trillion.
1 hour ago
Flagship Pioneering, investor in Moderna raises $3.4 billion funds

Flagship Pioneering, investor in Moderna raises $3.4 billion funds

Flagship Pioneering, the bioplatform company, and the venture capital investor in Moderna, today announced that it had raised additional funding of $2.23 billion, which brings its
1 day ago
United to recall furloughed employees as travel recovers

United to recall furloughed employees as travel recovers

The fading of the pandemic and the rollout of vaccines has brought in some good cheer for the floundering air travel industry. More countries have opened up for business and are al
2 days ago
UK’s Sanne agrees to consider Cinven bid

UK’s Sanne agrees to consider Cinven bid

Sanne, a UK fund administration business that provides alternative asset and corporate services, has agreed to hold talks with private equity firm Cinven over a potential £1.4bn t
2 days ago
Global stocks rise as investors ignore inflations indicators

Global stocks rise as investors ignore inflations indicators

Global stocks rose to an all-time high, with investor showing confidence in a strong economic recovery from coronavirus and the vaccine effect, but the market is still a bit cautio
2 days ago
UK watchdog whacks Amazon with probe for unfair data collection practices

UK watchdog whacks Amazon with probe for unfair data collection practices

The Competition and Markets Authority will focus on whether Amazon, Inc. favors merchants that use its delivery services.
5 days ago